Company code: Tinavi Medical Technologies Co.Ltd(688277) company abbreviation: Tinavi Medical Technologies Co.Ltd(688277) Tinavi Medical Technologies Co.Ltd(688277)
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 The company is not profitable at the time of listing and has not realized profit √ yes □ no
The company is a Innovation Medical Management Co.Ltd(002173) instrument enterprise committed to R & D, production and sales of Orthopaedic Surgery Siasun Robot&Automation Co.Ltd(300024) , which has the characteristics of high investment in early R & D and long time of approved listing and sales process. The company is listed in accordance with the listing standard specified in Item (II) of Article 22 of the review rules for the issuance and listing of shares on the science and Innovation Board of Shanghai Stock Exchange, and is not profitable at the time of listing. During the reporting period, the company achieved operating income of 156021900 yuan, net profit attributable to shareholders of listed company was 799332 million yuan, and net profit attributable to shareholders of listed company after deducting non recurring profit and loss was 103219 million yuan. During the reporting period, the company has not realized profit.
During the reporting period, the company continued to focus on the main business of Orthopaedic Surgery Siasun Robot&Automation Co.Ltd(300024) and around the established strategic planning, further increased the investment in research and development of new technologies and products, market expansion, clinical service capacity-building and other aspects, increased the costs and expenses of the current period, and the relevant benefits have not been reflected in the current period, which has a direct impact on the net profit. It is mainly reflected in the substantial increase of R & D expenses over the same period of last year: during the reporting period, R & D expenses increased by 48.14% year-on-year; During the reporting period, the proportion of R & D expenditure in operating revenue was about 70.37%.
At present, the company’s main product, orthopaedic surgery Siasun Robot&Automation Co.Ltd(300024) has entered the clinical operation, which is still in its infancy. Although the cognition of hospitals, doctors and patients on orthopaedic surgery Siasun Robot&Automation Co.Ltd(300024) surgery has increased rapidly in recent years, it will take some time for the overall cognition to reach a more ideal state. In the future, the company will continue to strive to expand market share, accelerate the implementation of application scenarios, focus on technological innovation and development, and continue to build an ecosystem with orthopaedic surgery Siasun Robot&Automation Co.Ltd(300024) platform as the core, so as to improve the core competitiveness of the company. 3、 Important risk warning: the company has elaborated various risks and countermeasures that the company may face in the process of operation in this report. Please refer to this report. 4、 All directors of the company attended the board meeting. 5、 Shanghui Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6、 Zhang Songgen, the person in charge of the company, Xing Yuzhu, the person in charge of accounting, and Qi Min, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan for converting accumulation fund into share capital adopted by the board of directors during the reporting period are none. VIII. Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable. IX. risk statement of forward-looking statements √ applicable □ not applicable
The company’s future plans, development strategies and other forward-looking statements involved in this report do not constitute the company’s substantive commitment to investors. Investors are reminded to pay attention to investment risks. 10、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties no Xi. Whether there is any external guarantee in violation of the specified decision-making procedures no XII. Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the annual report disclosed by the company no XIII. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section 4 corporate governance 38 Section V environment, social responsibility and other corporate governance 55 section VI important matters Section VII changes in shares and shareholders 86 Section VIII preferred shares Section 9 relevant information of corporate bonds 96 section x financial reporting ninety-six
The financial report containing the signatures and seals of the legal representative of the company, the person in charge of accounting and the person in charge of accounting organization.
The list of documents for reference, the text of all company documents and the original version of the announcement publicly disclosed on the website designated by the CSRC during the reporting period.
The original of the audit report with the seal of the accounting firm and the signature and seal of the certified public accountant.
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
Tinavi Medical Technologies Co.Ltd(688277) , the company and the company refer to Tinavi Medical Technologies Co.Ltd(688277)
The controlling shareholder and actual controller refers to Mr. Zhang Songgen
Zhihui hechuang refers to Beijing Zhihui hechuang investment partnership (limited partnership)
Zhihui Dechuang refers to Zhihui Dechuang (Tianjin) technology center (limited partnership)
Tinavi Medical Technologies Co.Ltd(688277) asset management plan refers to China Securities Co.Ltd(601066) Tinavi Medical Technologies Co.Ltd(688277) strategic placement collective asset management plan of science and innovation board
Advanced manufacturing fund refers to advanced manufacturing industry investment fund (limited partnership)
Beijing Tianjin Hebei fund refers to the Beijing Tianjin Hebei Industrial coordinated development investment fund (limited partnership)
Runxin Dingtai refers to Beijing Runxin Dingtai Investment Center (limited partnership)
Anhui Tinavi Medical Technologies Co.Ltd(688277) refers to Anhui Tinavi Medical Technologies Co.Ltd(688277) Medical Technology Co., Ltd
Shuimu Dongfang refers to Beijing Shuimu Dongfang medical Siasun Robot&Automation Co.Ltd(300024) Technology Innovation Center Co., Ltd
Tianhecheng refers to Beijing tianhecheng Medical Technology Co., Ltd
Intemedi refers to Beijing intemedi Technology Co., Ltd
Rosenbot refers to Beijing rosenbot Technology Co., Ltd
CLP Guokang refers to CLP Guokang Data Technology Co., Ltd
Hebin intelligent refers to Hefei Hebin intelligent Siasun Robot&Automation Co.Ltd(300024) Co., Ltd
Huigu medicine refers to Beijing Huigu Medical Technology Co., Ltd
Xinshiji medical refers to Beijing Xinshiji Medical Technology Co., Ltd
CSA refers to Canadian Standards Association
CFDA and the State Food and Drug Administration refer to the State Food and drug administration.
In March 2013, the State Food and drug administration was established. In March 2018, according to the requirements of the plan for deepening the reform of Party and state institutions, the State Food and Drug Administration and the State Administration for Industry and commerce were integrated into the state market supervision and administration, and a separate state drug administration was established, which was managed by the state market supervision and Administration
Nmpa and the State Food and Drug Administration refer to the National Medical Products Administration (nmpa)
CE means that CE is a safety certification mark, and the European drug administration implements CE certification for medical devices
CSRC and CSRC refer to the China Securities Regulatory Commission
Shanghai stock exchange refers to Shanghai Stock Exchange
Company Law refers to the company law of the people’s Republic of China
Securities Law refers to the securities law of the people’s Republic of China
The articles of association refers to the Tinavi Medical Technologies Co.Ltd(688277) articles of association, the current articles of association of the company
The articles of Association (Draft) refers to the Tinavi Medical Technologies Co.Ltd(688277) articles of Association (Draft), which will be applicable after the company’s issuance and listing
China Securities Co.Ltd(601066) securities, sponsor, refers to China Securities Co.Ltd(601066)
Sponsor
Certified Public Accountants and Shanghui certified public accountants refer to Shanghui Certified Public Accountants (special general partnership)
Yuan, ten thousand yuan and one hundred million yuan refer to RMB, ten thousand yuan and one hundred million yuan unless otherwise specified
The reporting period refers to 2021
Mm is the length in millimeters
Section II Company Profile and main financial indicators
1、 Basic information of the company
Chinese name of the company Tinavi Medical Technologies Co.Ltd(688277)
Chinese abbreviation of the company Tinavi Medical Technologies Co.Ltd(688277)
The foreign language name of the company is tinavi medical technologies Co., Ltd
The abbreviation of the company’s foreign name is tinavi
Legal representative of the company: Zhang Songgen
Registered address: room 206, floor 2, building 1, Dongsheng Science Park, No. 66, xixiaokou Road, Haidian District, Beijing
The historical change of the company’s registered address is not applicable
Office address of the company: 2F, building 7, Beijing Centergate Technologies (Holding) Co.Ltd(000931) Dongsheng International Science Park, No. 1, yongtaizhuang North Road, Haidian District, Beijing
The postal code of the company’s office address is 100192
Company website: www.tinavi.com com.
E-mail [email protected].
2、 Contact person and contact information
Secretary of the board of directors (domestic representative of information disclosure) securities affairs representative
Name: Huang Junhui, sun Xiaoyan
Contact address Beijing Centergate Technologies (Holding) Co.Ltd(000931) dongshengguo, No. 1, yongtaizhuang North Road, Haidian District, Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) dongshengji Science Park, No. 1, yongtaizhuang North Road, Haidian District, Beijing
Tel: 010821566608009 010821566608009
Fax: 01062968128
E-mail [email protected]. [email protected].
3、 Information disclosure and preparation location
The media name and website of the annual report disclosed by the company include Shanghai Securities News, China Securities News, securities times and Securities Daily
Website of the stock exchange where the company discloses the annual report website of Shanghai Stock Exchange (www.sse. Com. CN.)
The company’s annual report is prepared at the Securities Investment Department of the company on the second floor of building 7, Beijing Centergate Technologies (Holding) Co.Ltd(000931) Dongsheng International Science Park, No. 1, yongtaizhuang North Road, Haidian District, Beijing
4、 Company stock / depositary receipts profile (I) company stock profile √ applicable □ not applicable
Company stock profile
Stock type stock exchange and sector stock abbreviation stock abbreviation before stock code change
RMB ordinary shares (A shares) Shanghai Stock Exchange Kechuang board
